Tag: OTCQX:DMPI

May 25, 2016

DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083

DelMar Pharmaceuticals (OTCQX:DMPI) announced the successful completion of an End of Phase 2 meeting with the U.S. Food and Drug...
May 19, 2016

DelMar Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Senior Exchange Uplisting

DelMar Pharmaceuticals (OTCQX:DMPI) announced a 1-for-4 reverse stock split of its authorized, issued and outstanding common stock in preparation for...
May 13, 2016

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results

DelMar Pharmaceuticals (OTCQX:DMPI) announced its financial results for the quarter ending March 31, 2016, the third quarter of the 2016...
May 5, 2016

DelMar Pharmaceuticals Announces $5.6 Million Private Placement Of Preferred Shares

DelMar Pharmaceuticals (OTCQX:DMPI) announced a closing of a private placement of Preferred Shares for gross proceeds of $5.6 million, and...
April 29, 2016

The Richmond Club: DelMar Pharmaceuticals

The Richmond Club recent released an Investor Presentation highlighting DelMar Pharmaceuticals (OTCQX:DMPI).
April 21, 2016

FDA Grants DelMar Pharmaceuticals Orphan Drug Designation For VAL-083 In Ovarian Cancer

DelMar Pharmaceuticals (OTCQX:DMPI) announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for...
April 19, 2016

DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at AACR Annual Meeting

DelMar Pharmaceuticals (OTCQX:DMPI) presented updated data from an ongoing Phase I/II clinical trial in refractory glioblastoma multiforme (GBM) with its...